Supply Chain Director must decide how to respond to a critical active ingredient supplier rupture
Market Context
In September 2024, over 320 essential drugs were in shortage in the US—a historical record. Hurricane Helene destroyed the Baxter plant, collapsing IV fluids nationwide. Over 50% of pharmaceuticals are manufactured overseas with critical dependence on APIs from China and India. In this scenario, the main supplier failed, lead time expanded from 45 to 120 days, and the production line for 3 drugs stopped.
Sources: ASHP Shortage List Sep/2024 · HHS/ASPE White Paper 2025 · APIIC Annual Report 2025
High urgency—MAT-4 impact. 5 alternatives: qualified alternative supplier, emergency import, outsourcing, internal production, accept rupture. Each with an FDA compliance flag.
Alternative supplier activated in 18 days. Weekly monitoring: OTIF, batch quality, line availability. Alert in week 3—batch with specification deviation. Batch rejected before entering the line.
Director confirms: achieved result. Production resumed in 22 days. Revenue protected in 2 out of 3 drugs. The third took an additional 45 days—but with a complete regulatory trail for the FDA.
Without governance (Standard)
- × Decision made by phone between 3 directors without record
- × Alternative supplier activated without compliance verification
- × Deviating batch enters the line—recall necessary
- × FDA opens a process due to lack of traceability
- × Next rupture: same rush. No precedent.
With Arcogi governance
- ✓ 5 alternatives with regulatory flag per option—before deciding
- ✓ Deviating batch intercepted in week 3—before usage
- ✓ Complete regulatory trail for FDA audit
- ✓ Production resumed in 22 days with alternative supplier
- ✓ Precedent registered—next rupture starts faster
Healthcare — API Rupture
Without Arcogi
The ERP issues a rupture alert. From there, the decision fragments: supply chain, regulatory, and quality teams start discussing in parallel channels, under time pressure. An alternative supplier appears, the endorsement happens sparsely, and the choice proceeds without a formal process that registers alternatives, criteria, responsibilities, and involved risks.
The problem is not just acting fast. It's acting without a clear trail of why that decision was made, among which options, and with what evidence base.
When a quality deviation arises, the organization no longer faces just an operational problem. It now faces a traceability, regulatory defensibility, and executive responsibility problem.
With Arcogi
Arcogi organizes the decision before urgency disorganizes the operation.
Alternatives are structured with their impacts, restrictions, and regulatory flags. The evaluation no longer happens in scattered messages and begins to follow a formal trail, with explicit responsibilities, clear criteria, and registered approval before any critical advancement.
Execution is tracked, and monitoring allows identifying deviations in time to correct course before the problem advances to the line or the market.
If there is regulatory questioning, the decision dossier already exists: who decided, among which alternatives, based on what evidence, and with what observed result.
Why this matters to the C-level
Because, in the agentic era, finding an alternative can be fast.
What remains rare — and decisive — is responding with speed and governance.
Arcogi reduces the risk of transforming operational urgency into regulatory exposure, creating the layer that connects decision, responsibility, and traceability in high-impact contexts.
Essential
Full cycle with compliance per alternative + trail for the FDA. Director confirms result in 60 days. Company has an auditable dossier. No batch monitoring.
Complete
Everything in Essential + weekly OTIF and quality monitoring. Deviating batch detected automatically in week 3—before entering the line. One interception like this pays for the framework for years.
"The problem was never the rupture. Ruptures happen. The problem was having no trail of how we responded—and discovering the bad batch after it was already inside the patient."